CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Atezolizumabdrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02451423
NCT02451423Phase 2Completed
CompareCT.gov

Phase II Study of Neoadjuvant Atezolizumab-based Immunotherapy for Patients With Urothelial Carcinoma (NEBULA)

Lawrence Fong·interventional·Posted May 22, 2015·Updated May 31, 2024

In Brief

A Phase 2 clinical trial evaluating Atezolizumab for Carcinoma, Transitional Cell. Completed, enrolled 23 participants across 1 site.

Detailed Summary

This phase II trial studies the best dose of atezolizumab in treating patients with bladder cancer that has not spread to other places in the body. Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Transitional Cell
CountriesUnited States
CollaboratorsGenentech, Inc., Bladder Cancer Advocacy Network, Conquer Cancer Foundation, National Cancer Institute (NCI), The V Foundation

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 22, 2015
Enrollment StartMar 29, 2016
Primary CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 11.1 years ago

Interventions

Atezolizumabdrug

1200 mg Given IV